{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpes+Simplex+Virus+2&page=2",
    "query": {
      "condition": "Herpes Simplex Virus 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Herpes+Simplex+Virus+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T09:00:15.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00023582",
      "title": "HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections",
        "Herpes Genitalis",
        "HIV Seronegativity",
        "Syphilis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 250,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-08-08",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00023582"
    },
    {
      "nct_id": "NCT02615470",
      "title": "Enhancing a Sustainable Pharmacy-based Immunization Program in Two States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Zoster",
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "Enhanced immunization delivery model",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Immunization update",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Auburn University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2015-11",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-20",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 2,
      "location_summary": "Auburn, Alabama • Claremont, California",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "Claremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02615470"
    },
    {
      "nct_id": "NCT05432583",
      "title": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "BNT163",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 318,
      "start_date": "2022-12-08",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 6,
      "location_summary": "Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05432583"
    },
    {
      "nct_id": "NCT06033261",
      "title": "A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "mRNA-1608",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BEXSERO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 303,
      "start_date": "2023-09-06",
      "completion_date": "2025-04-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06033261"
    },
    {
      "nct_id": "NCT00803543",
      "title": "Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2009-01",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803543"
    },
    {
      "nct_id": "NCT04762511",
      "title": "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "name": "Lower dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Medium dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose formulation of HSV vaccine (GSK4108771A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-02",
      "completion_date": "2021-05-26",
      "has_results": false,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Rochester, New York",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762511"
    },
    {
      "nct_id": "NCT00057330",
      "title": "HerpeVac Trial for Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8323,
      "start_date": "2003-01-14",
      "completion_date": "2009-08-22",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057330"
    },
    {
      "nct_id": "NCT06698575",
      "title": "A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "name": "ABI-1179",
          "type": "DRUG"
        },
        {
          "name": "ABI-1179 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 103,
      "start_date": "2024-12-08",
      "completion_date": "2026-01-19",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 4,
      "location_summary": "Kansas City, Missouri • Rochester, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698575"
    },
    {
      "nct_id": "NCT00655434",
      "title": "HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Herpes Simplex Virus 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Focus Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2008-03",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2009-01-09",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 1,
      "location_summary": "Burbank, California",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655434"
    },
    {
      "nct_id": "NCT05831111",
      "title": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1195.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1195.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1189",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1195",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 482,
      "start_date": "2023-04-05",
      "completion_date": "2026-10-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-07-24T09:00:15.837Z",
      "location_count": 34,
      "location_summary": "Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831111"
    }
  ]
}